{"id":1485,"date":"2026-08-03T17:36:00","date_gmt":"2026-08-03T17:36:00","guid":{"rendered":"https:\/\/quickening.zapto.org\/wordpress\/?p=1485"},"modified":"2026-09-13T15:08:18","modified_gmt":"2026-09-13T15:08:18","slug":"vitamins-and-minerals","status":"publish","type":"post","link":"https:\/\/quickening.zapto.org\/wordpress\/?p=1485","title":{"rendered":"2. Vitamins and Minerals"},"content":{"rendered":"\n

The First Step of My Quest<\/em><\/h3>\n\n\n\n

In 1996, Larry Clark published the results of a randomized, double-blind, placebo-controlled trial in the Journal of the American Medical Association<\/em>. He had enrolled 1,312 patients and given half of them 200 micrograms of selenium per day. The trial was stopped before its scheduled completion.<\/p>\n\n\n\n

The reason a trial gets stopped early is that the results become so unambiguous that continuing to give the placebo group a placebo is considered unethical. Clark’s trial produced a 50% reduction in total cancer mortality and a 37% reduction in total cancer incidence. Prostate cancer incidence dropped 63%. Colorectal cancer incidence dropped 58%. Lung cancer incidence dropped 46%.<\/p>\n\n\n\n

For a single trace mineral costing a few cents a day. 200 micrograms of selenium is roughly 1\/300th of a single grain of table salt. <\/p>\n\n\n\n

The medical establishment’s response to this result was, essentially, to ignore it. A decade later, the National Cancer Institute funded the Selenium and Vitamin E Cancer Prevention Trial, called SELECT, to replicate Clark’s findings at scale. Life Extension Magazine predicted in 2008 that SELECT would fail. Not because selenium doesn’t work. Because SELECT was designed to use the wrong form of it.<\/p>\n\n\n\n

Clark’s trial used selenized yeast, a form of selenium that closely resembles dietary selenium in its biological activity. SELECT used l-selenomethionine, a different chemical form with different bioavailability and different tissue distribution. SELECT also used all-racemic alpha-tocopherol as its vitamin E which is a synthetic form that depletes gamma-tocopherol, the naturally occurring form that epidemiological data had already associated with dramatically lower prostate cancer risk. Men supplemented with alpha-tocopherol in SELECT experienced a 45-48% depletion of gamma-tocopherol by six months, sustained for the five-year duration of the trial.<\/p>\n\n\n\n

SELECT found no benefit from either nutrient. This was presented to the public as proof that selenium and vitamin E do not prevent prostate cancer. The distinction between the form of selenium that worked and the form that was tested was mentioned nowhere in the press coverage. The 63% reduction in prostate cancer incidence from Clark’s trial was not mentioned either. A study using the wrong molecules produced a negative result that then served to erase a study using the right ones.<\/p>\n\n\n\n

The researchers deliberately designed SELECT to fail. This is the pattern. Understanding it is prerequisite to reading the literature.<\/p>\n\n\n\n

\n\n\n\n

How to Build a Study That Fails<\/h2>\n\n\n\n

The pharmaceutical drug trial model was developed to evaluate a specific kind of intervention: a synthetic molecule at a specific dose, administered to a population with a specific condition, over a defined period, compared against a true placebo. This model has produced genuine medical advances and its methodological rigor is real.<\/p>\n\n\n\n

It is also almost perfectly designed to produce negative results when applied to vitamins and minerals.<\/p>\n\n\n\n

A drug has no baseline level in the human body. A vitamin does. You cannot design a true placebo group for a vitamin D trial because every participant already has some vitamin D in their blood from sun exposure and diet, and that baseline level varies enormously from person to person. The researchers can give placebo pills, but the “control condition” is not absence of the intervention. It is an unknown, varying, unmeasured quantity of the same intervention.<\/p>\n\n\n\n

A drug acts through one or two specific molecular targets. A vitamin acts through dozens of simultaneous pathways, many of them interdependent. Designing a study to detect the effects of vitamin D without accounting for the subject’s magnesium status \u2014 which is required for vitamin D activation \u2014 will underestimate the effect of vitamin D in magnesium-deficient subjects, which in a typical American population is a substantial majority.<\/p>\n\n\n\n

A drug’s effects can often be detected in weeks or months. The diseases that vitamins and minerals modulate, like cancer, cardiovascular disease, and neurodegeneration, develop over decades. A five-year trial of selenium supplementation will detect less effect than a twenty-year trial, not because selenium is less effective but because the cancers that selenium prevents had not yet appeared in the five-year window.<\/p>\n\n\n\n

The researchers who conducted the United States Preventive Services Task Force analysis of multivitamins in 2013 acknowledged all of this in their own paper. They wrote that their methodology was “used primarily to evaluate drug therapy” and “might not be ideally suited to evaluating nutrients.” They admitted that “physiologic systems affected by vitamins and other antioxidant supplements are so complex that the effects of supplementing with only one or two components is generally ineffective.” They noted that “the best support for benefit of supplementation came from two multivitamin trials that used physiologic doses of a wider variety of agents.”<\/p>\n\n\n\n

Having made these admissions, they proceeded to conclude that the evidence does not support vitamin and mineral supplementation for cancer or cardiovascular disease prevention.<\/p>\n\n\n\n

Their analysis defined a “multivitamin” as a formulation containing as few as three nutrients. Out of 154 clinical trials with “multivitamin” appearing in the title in PubMed, they deemed only two methodologically sufficient for inclusion. A single trial on women was included, and the “multivitamin” in that trial contained five ingredients. The researchers themselves conceded that “it could be argued that there are no data on a true multivitamin in women included in this analysis.”<\/p>\n\n\n\n

This is not a failure of rigor. It is rigor deployed in service of a predetermined conclusion.<\/p>\n\n\n\n

\n\n\n\n

What the Data Says Despite the Methodology<\/h2>\n\n\n\n

The more revealing exercise is to read what the USPSTF analysis actually found and buried.<\/p>\n\n\n\n

The Physicians’ Health Study II (PHS-II) enrolled male physicians, gave them a genuine multivitamin for 11.2 years, and found an 8% reduction in overall cancer incidence, a 12% reduction in cancer death, and a 39% reduction in fatal heart attack risk. These are not marginal results. A 39% reduction in fatal heart attack risk from a multivitamin taken for eleven years is a finding that, announced for a pharmaceutical drug, would generate front-page coverage and a Nobel Prize discussion.<\/p>\n\n\n\n

The SU.VI.MAX trial found a 31% reduction in total cancer incidence in men over 7.5 years of multivitamin supplementation.<\/p>\n\n\n\n

When SU.VI.MAX and PHS-II results were pooled across ten years of follow-up, cancer risk was reduced in both. The USPSTF researchers performed this pooled analysis and then did not present it prominently in their conclusions.<\/p>\n\n\n\n

A single trial found a 58% reduction in cancer incidence for subjects supplementing with vitamin D plus calcium over four years. Another found a 45% reduction in overall cancer risk for calcium supplement users.<\/p>\n\n\n\n

The European Prospective Investigation into Cancer and Nutrition \u2014 EPIC-Heidelberg \u2014 enrolled 23,943 subjects and followed them for an average of eleven years. Individuals who used antioxidant vitamin supplements were 48% less likely to die from cancer and 42% less likely to die from any cause compared to non-users.<\/p>\n\n\n\n

All of this is inside the research literature. None of it reaches the public as a headline. What reaches the public is SELECT \u2014 the study that used the wrong molecules and found no benefit \u2014 rephrased as “Selenium and Vitamin E Found Ineffective.”<\/p>\n\n\n\n

The asymmetry is not accidental. It is structural and well-funded.<\/p>\n\n\n\n

\n\n\n\n

Follow the Incentive<\/h2>\n\n\n\n

A pharmaceutical company that patents a molecule can recover its research investment through exclusive market rights. The research funding, the clinical trials, the FDA approval process, the physician education campaigns, the direct-to-consumer advertising \u2014 all of it is financed by the margin between the cost of the molecule and the price the patent allows the company to charge.<\/p>\n\n\n\n

Selenium is a mineral. It occurs in soil. No one can patent it. The same is true of vitamin D, vitamin C, magnesium, zinc, and every other micronutrient this chapter concerns. The economic model that funds pharmaceutical research does not exist for any of them.<\/p>\n\n\n\n

What exists instead is a reverse incentive. The supplement market competes with the pharmaceutical market for the same patients and the same dollars. A patient who prevents cancer with selenium is not a patient who buys chemotherapy. A patient who maintains cardiovascular health with a multivitamin over twenty years is not a patient who takes statins for twenty years. The economic interest of the pharmaceutical industry is not served by research that produces positive results for cheap non-patentable compounds.<\/p>\n\n\n\n

The system steers people toward pharmaceuticals through a mechanism so familiar it has become invisible: insurance pays for drugs, not supplements. The patient who pays $10 for a statin copay and $80 out of pocket for CoQ10 \u2014 the compound the statin depletes \u2014 experiences the statin as nearly free and the CoQ10 as expensive, even though the combined cost of the statin plus its side effect management exceeds what the supplement protocol would have cost. The insurance architecture was designed around pharmaceutical interventions. Supplements don’t exist in that architecture. The result is a population that perceives drugs as cheap and supplements as expensive, when the actual economics run in the opposite direction for many conditions. Follow the incentive: the pharmaceutical company has a reimbursement pathway, the supplement manufacturer does not. The doctor who prescribes the drug generates a billable interaction. The conversation about supplements generates nothing.<\/p>\n\n\n\n

The USPSTF is funded by the Agency for Healthcare Research and Quality, which operates within the Department of Health and Human Services, which is staffed substantially by physicians trained within an educational system funded substantially by pharmaceutical companies. The connections are not conspiratorial. They do not need to be. Institutional bias does not require conspiracy. It requires only that the people making decisions about what to fund, what methodology to apply, and what conclusions to publicize share a set of professional assumptions about what counts as evidence and whose evidence counts.<\/p>\n\n\n\n

I have been reading this literature since 1982. I have read dozens of studies over the years directly comparing some widely taken pharmaceutical drug with a food-derived nutraceutical, typically finding that the nutraceutical is at least as effective but with fewer side-effects. No doubt there are hundreds more. The positive findings accumulate steadily in the primary literature and vanish almost entirely before they reach the public. The negative findings, particularly the ones produced by methodologically compromised studies using wrong forms of nutrients at inadequate doses for insufficient durations, become headlines and policy statements.<\/p>\n\n\n\n

The real crime seems to me to be not the pharmaceutical industry’s behavior, which is at least economically rational, but the behavior of the federal agencies whose statutory purpose is public health and whose demonstrated practice is the suppression of data that threatens their institutional relationships.<\/p>\n\n\n\n

\n\n\n\n

The Undebatable Cases<\/h2>\n\n\n\n

Some vitamin and mineral findings meet any reasonable standard of evidence.<\/p>\n\n\n\n

Vitamin D<\/strong> deficiency is associated with increased all-cause mortality in every large population study that has examined it. The VITAL trial \u2014 25,000 participants, five years, rigorous RCT \u2014 found that vitamin D3 supplementation reduced cancer mortality by 25% overall and by significantly more in normal-weight individuals. This is a large, well-powered, recent, double-blind trial. There is no methodological objection to it that does not equally invalidate pharmaceutical drug trials.<\/p>\n\n\n\n

Selenium<\/strong> supplementation in the Clark trial produced results so robust the trial was stopped early. The ethical threshold for stopping a trial early is a high one. The data has to be so clear that continuing would be unconscionable. That threshold was crossed.<\/p>\n\n\n\n

Magnesium<\/strong> deficiency is present in an estimated 50-60% of Americans and is associated with cardiovascular disease, type 2 diabetes, hypertension, and neurological dysfunction. Magnesium is required for over 300 enzymatic reactions including the activation of vitamin D. A population deficient in magnesium is a population that will show attenuated results in vitamin D trials. This is rarely controlled for.<\/p>\n\n\n\n

Zinc<\/strong> deficiency impairs testosterone synthesis, immune function, and wound healing. Vegetarians and older adults are at elevated risk due to reduced absorption from plant-based diets (from phytates) and declining gastric acid production respectively. Zinc status is rarely measured in clinical practice.<\/p>\n\n\n\n

These are not disputed. They appear in standard biochemistry textbooks. The medical establishment’s response to them is to note them in specialty literature and ignore them in clinical practice, because there is no drug to prescribe and no reimbursement code to bill.<\/p>\n\n\n\n

But there are many more which are deficient in the modern American Diet:<\/p>\n\n\n\n

Nutrient<\/td>Deficient<\/td>Key Symptoms<\/td><\/tr>
K2<\/td>Vast majority<\/td>Arterial stiffness, dental issues<\/td><\/tr>
Iodine<\/td>Rising<\/td>Hypothyroid, brain fog, breast tenderness<\/td><\/tr>
Choline<\/td>~90%<\/td>Fatty liver, brain fog, poor methylation<\/td><\/tr>
Iron<\/td>~10-20%<\/td>Fatigue, cold intolerance, brain fog<\/td><\/tr>
Boron<\/td>Widespread<\/td>Low T, poor bone density, arthritis<\/td><\/tr>
Omega-3s<\/td>>80%<\/td>Inflammation, depression, dry skin<\/td><\/tr>
C<\/td>Majority<\/td>Skin & joint problems, cancer, inflammation<\/td><\/tr><\/tbody><\/table>
summary by alter.systems<\/figcaption><\/figure>\n\n\n\n

Still more become deficient under certain circumstances:<\/p>\n\n\n\n

    \n
  • Soil-depleted minerals – Selenium, chromium, molybdenum, boron, iodine<\/li>\n\n\n\n
  • Diet-stripped nutrients – Glycine, taurine, vitamin C<\/li>\n\n\n\n
  • Drug-depleted nutrients – CoQ10 (statins), B6 (birth control), B1 (metformin)<\/li>\n\n\n\n
  • Age-declining synthesis – CoQ10, taurine, B12 <\/li>\n\n\n\n
  • American diet also lacks glycine, taurine, choline, ergothioneine<\/li>\n<\/ul>\n\n\n\n

    I will describe how and why I take these nutrients in subsequent chapters.<\/p>\n\n\n\n

    \n\n\n\n

    The medical establishment’s standard assurance \u2014 that a balanced diet provides everything the body needs \u2014 is not wrong in principle. It describes a genuinely varied, whole food, mineral-dense, phytochemical-rich diet consumed by someone with adequate sun exposure, healthy gut microbiome, and no obesogen or environmental toxin burden. This diet exists in centenarian populations in the Caucasus, Sardinia, and Okinawa. It does not describe what most Americans eat. The balanced diet that provides everything you need is not a hamburger with fries and a milkshake \u2014 but that is the diet the epidemiology of common nutrient deficiencies is measuring. Selenium deficiency documented in regions with depleted soils. Zinc insufficiency producing the taste sensitivity loss that blunts appreciation of subtle flavors and the DNA repair impairment that blunts cancer surveillance simultaneously. Magnesium deficiency in 50% of Americans from soil depletion and food processing. Vitamin D deficiency in the same percentage from indoor living eliminating what the balanced diet assumption required from sun exposure.<\/p>\n\n\n\n

    The supplements are not additions to an adequate diet. They are corrections to a food supply that the balanced diet assumption was designed for and that industrial agriculture, food processing, and indoor living have progressively dismantled.<\/p>\n\n\n\n

    \n\n\n\n

    The RDA: From Wartime Guideline to Regulatory Weapon<\/h2>\n\n\n\n

    The Recommended Dietary Allowance has a history that most people who rely on it don’t know \u2014 and that history explains why the supplement protocol in this book exists at all.<\/p>\n\n\n\n

    The concept originated in 1941 as a wartime nutritional standard, developed by the National Academy of Sciences to ensure military recruits and the civilian population weren’t malnourished during food rationing. The goal was explicitly minimal: prevent deficiency diseases. Scurvy, pellagra, beriberi \u2014 the diseases of severe deprivation. The standard was never designed to establish optimal intake for health, longevity, or disease prevention. It was designed to keep people functional enough to fight a war.<\/p>\n\n\n\n

    The RDA might have remained an obscure wartime guideline if the FDA hadn’t decided in 1962 to weaponize it as a regulatory ceiling. The FDA proposed that any vitamin or mineral supplement containing more than 150% of the RDA would be legally classified as an unapproved drug \u2014 subject to the same approval requirements as pharmaceutical medications. Simultaneously, they proposed mandating a disclaimer on all supplement labels: “Vitamins and minerals are supplied in abundant amounts by commonly available foods. Except for persons with special medical needs, there is no scientific basis for recommending routine use of dietary supplements.”<\/em><\/p>\n\n\n\n

    The disclaimer tells you exactly what the institutional position was: supplements are unnecessary, the food supply is adequate, and anyone recommending otherwise lacks scientific basis. This was the FDA’s official position, proposed as mandatory label text for every supplement sold in America.<\/p>\n\n\n\n

    The public and industry response was fierce. Congressional hearings from 1968 to 1970 produced enough pushback that the FDA dropped the mandatory disclaimer \u2014 but finalized the rest of the rule in 1973, officially establishing the U.S. RDA as the legal standard for supplement labeling.<\/p>\n\n\n\n

    The 1973 finalization and pushback was recent history to me when I started reading the alternative health literature in 1982. The regulatory battle had concluded less than a decade earlier. Linus Pauling’s extensive documentation of his attempts to present vitamin C evidence to the RDA board \u2014 and their systematic refusal to consider it \u2014 was happening against this backdrop. He wasn’t just arguing with scientific conservatism. He was arguing with an institution that had officially declared there was no scientific basis for supplementation beyond its own guidelines.<\/p>\n\n\n\n

    The Proxmire Amendment of 1976 changed the legal landscape. Senator William Proxmire introduced legislation stripping the FDA of authority to cap supplement doses or classify supplements as drugs based solely on potency. Congress passed it. The FDA lost the power to limit what could be sold as a supplement.<\/p>\n\n\n\n

    Without the Proxmire Amendment, the supplement protocol in this book would consist largely of illegal products. Therapeutic doses of vitamin C, the selenium levels documented to reduce cancer risk, the vitamin D levels required for immune function and epigenetic clock effects \u2014 all would have been classified as unapproved drugs under the 1973 rule.<\/p>\n\n\n\n

    The person who read Pauling and Passwater in 1982 and decided to inform themselves about what the evidence actually supported was making a specific decision in a specific regulatory context: the institutions had declared the question settled, the evidence said otherwise, and the legal right to act on that evidence had been secured only six years earlier by a Congressional amendment over the FDA’s objection.<\/p>\n\n\n\n

    This was my first lesson in institutional capture and the intellectual dishonesty of the “experts”. The FDA’s position served the food industry’s interest in not having its products compared unfavorably to supplements. The RDA that declared the food supply adequate was convenient for an industry that had been depleting that food supply since the introduction of industrial processing in the early twentieth century. The regulatory framework that emerged wasn’t designed to protect consumers. It was designed to protect a food system.<\/p>\n\n\n\n

    Taking responsibility for your own nutritional status means reading the primary literature, making your own assessment of the evidence, and implementing what it justified. I was making not just a health decision in 1982, but setting a course of intellectual independence against an institutional consensus determined to make that independence obsolete.<\/p>\n\n\n\n

    For global audiences however, the regulatory freedom that makes the protocol in this book legally available in the United States was not won everywhere. The European Union’s Food Supplements Directive established maximum permitted levels for vitamins and minerals that restrict optimal or therapeutic dosing available to American consumers. The selenium levels documented to reduce cancer risk, the vitamin D doses required for immune function and epigenetic clock effects, the vitamin C levels Pauling advocated all face legal restrictions in EU member states that American consumers avoided through the Proxmire Amendment. The global reader implementing this protocol should verify local regulatory status for specific compounds and doses.<\/p>\n\n\n\n

    \n\n\n\n

    What I Have Been Doing Since 1980<\/h2>\n\n\n\n

    In 1980, I confess that I began supplementing with a typical RDA multivitamin. I won’t say the brand name because it’s so embarrassing. Not long after that I started reading alternative health books and the primary literature directly rather than waiting for institutional consensus and approval. The institutional consensus, as this chapter has documented, tends to arrive either never or inverted. I learned that that typical drug store multivitamin was little more than a placebo. Over the years I have settled on what seems to me to be optimum levels for me. I won’t elaborate on what those are here, because everyone is different and probably needs different amounts than what I take. However, I will list everything I take in Appendix B.<\/p>\n\n\n\n

    What I read then was the precursor literature to what Clark would publish in 1996: the epidemiological associations between selenium status and cancer incidence, the mechanistic research on antioxidant enzymes, the early vitamin D research on immune modulation, the zinc-testosterone connection, the magnesium-enzyme cofactor work. The conclusions were already visible in the data. They simply had not been packaged into headlines.<\/p>\n\n\n\n

    Four decades later the headlines have occasionally caught up. The VITAL trial. The NPC trial before it. The EPIC-Heidelberg data. The epidemiological literature on vitamin D is now substantial enough that even the USPSTF has partially reversed its earlier position.<\/p>\n\n\n\n

    The data did not change. The data was always there. What changed is that the accumulation became too large to ignore with a straight face.<\/p>\n\n\n\n

    The chapter on combining interventions will address the question nobody has answered: what happens when you add up forty years of these individually validated effects across independent biological pathways. The arithmetic is not in the literature. It is in a life.<\/p>\n\n\n\n

    \n","protected":false},"excerpt":{"rendered":"

    The First Step of My Quest In 1996, Larry Clark published the results of a randomized, double-blind, placebo-controlled trial in the Journal of the American Medical Association. He had enrolled 1,312 patients and given half of them 200 micrograms of selenium per day. The trial was stopped before its scheduled completion. The reason a trial […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/1485"}],"collection":[{"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1485"}],"version-history":[{"count":36,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/1485\/revisions"}],"predecessor-version":[{"id":2426,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/1485\/revisions\/2426"}],"wp:attachment":[{"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickening.zapto.org\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}